Konruns(SH:603590) Xin Lang Cai Jing·2025-09-05 07:53Group 1 - The core point of the article is that Kangchen Pharmaceutical's innovative drug KC1036 has been included in the "Children's Antitumor Drug Research and Development Encouragement Pilot Program (Starlight Program)" by the National Medical Products Administration [1] - The company will actively report progress or results related to the implementation framework required by the drug review center to jointly promote the clinical development and market launch of KC1036 in the field of pediatric Ewing's sarcoma [1] - Additionally, the company's controlling shareholder, Liu Jianhua, plans to reduce his holdings by a total of no more than 4.7807 million shares, which is not more than 3% of the company's total shares, through centralized bidding and block trading [1]